QCLS · XBRL financial data
Q/C Technologies financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (QCLS's year ends in late December)
- † Share count changed about 1/24 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/42 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (QCLS's year ends in late December)
- † Share count changed about 1/24 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/42 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (QCLS's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | †Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | †Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | 4,043 | (2,364)* | (9,800) | (9,566) | (1,929) | (2,064)* | (1,125) | (1,796) | (2,811) | (5,895)* | (1,243) | (6,616) |
| Stock-based compensation | 596 | 708* | 517 | 440 | 14 | 87* | 85 | 105 | 0* | 1,985* | 59 | 2,374 |
| Net cash from operating activities | (3,156)* | (1,933)* | (1,912) | (2,669)* | (3,632)* | (764)* | (2,640) | (2,065)* | (1,160)* | (3,200)* | (3,287) | (1,819)* |
| Net cash from investing activities | 3,361* | 5,934* | 732 | (11,021)* | 3,086* | 1,102* | 2,540 | 2,200* | (1,495)* | (11,669)* | 2,973 | 1,041* |
| Proceeds from issuing equity | — | — | — | — | — | — | — | — | 6,700 | — | — | — |
| Dividends paid | — | — | — | — | 68* | — | — | — | — | — | — | — |
| Net cash from financing activities | 0* | (1,619)* | (1,275) | 14,000* | 1,202* | (1,357)* | — | — | — | 8,952* | 454 | (43)* |
| Net change in cash | 204* | 2,383* | (2,455) | 310* | 656* | (1,019)* | (100) | 134* | 6,697* | (5,917)* | 141 | (820)* |
- † Share count changed about 1/24 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/42 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Q/C Technologies | 308 | not reported | (1,819)* | 8.2M | 6.0 quarters | 10-QJun 30, 2026 |
| Polomar Health Services | 179 | 1,529 | 121* | 28.4M | — | 10-QJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Jaguar Health | 3,788 | 1,225 | (5,338)* | not reported | 0.7 quarters | 10-QJun 30, 2026 |
| Integrated Biopharma | 4,471 | not reported | (1,194)* | 31.1M | 3.7 quarters | 10-KJun 30, 2026 |
| Theriva Biologics | 11,337 | 0* | (3,085)* | 45.9M | 3.7 quarters | 10-QJun 30, 2026 |
| PTC Therapeutics | 508,894 | 357,807 | (25,311)* | 83.5M | — | 10-QSep 30, 2026 |
| Inhibitor Therapeutics | 516 | not reported | (775)* | 173.8M | 0.7 quarters | 10-QJun 30, 2026 |
| Healthy Extracts | 190 | 2,067 | 306* | 14.7M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.